(Unless otherwise noted, all dollar amounts in this release are expressed in U.S dollars.) TORONTO, June 13, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or the “Company”) is pleased to announce that it has agreed with Adriatic Metals plc (“Adriatic”) to the terms of an acquisition of the entire issued, and
Q4 Remaining Performance Obligations up 41% to $138 billion Q4 GAAP Earnings per Share $1.19, non-GAAP Earnings per Share $1.70 Q4 Total Revenue $15.9 billion, up 11% Q4 Cloud Revenue (IaaS plus SaaS) $6.7 billion, up 27% Q4 Cloud Infrastructure (IaaS) Revenue $3.0 billion, up 52% Q4 Cloud Application (SaaS) Revenue $3.7 billion, up 12%
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”, TSX: PVF.UN TSX:PVF.PR.U) announced today its financial results for the three months ended March 31, 2025. All amounts are stated in U.S. dollars. The Partnership recorded net income of $24.6 million for the three months ended March 31, 2025, compared to net
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) — Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V, PVF.A) announced today its financial results for the three months ended March 31, 2025. All amounts are stated in U.S. dollars. The Company recorded net income of $972 million for the three months ended March 31, 2025, compared to
Key Financial Results: Net Income was $319 million, translating to diluted earnings per share (“EPS”) of $4.24, up 11% from a year ago Adjusted EPS* increased 22% year-over-year to $5.15 Gross profit* increased 19% year-over-year to $1,273 million Core G&A* increased 14% year-over-year to $413 million Adjusted pre-tax income* increased 23% year-over-year to $509 million
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 million $3.8
– Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting – Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE
Revenue Increases 26% to a Record $22.0 Million, Generating GAAP EPS of $0.24 BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended March 31, 2025. “We are extremely pleased to report another record-setting quarter, marking
TORONTO, May 07, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders, which was held via live webcast on Wednesday, May 7, 2025. A total of 132,500,374 common shares were voted at the meeting, representing
Headlines Revenue of $78M; free cash flow of $13.1M marks fourth consecutive positive quarter Company reiterates full-year guidance for revenue and raises full-year guidance for profitability and cash flow Continued innovation and customer momentum for Cerence xUI, the company’s next-gen platform BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”),